2024-05683. Pharmacokinetics in Patients With Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing; Guidance for Industry; Availability
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice of availability.
SUMMARY:
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing.” In general, drug development programs should be conducted so that when products are approved, the labeling provides appropriate dosing recommendations for patients with renal impairment. This guidance is intended to assist sponsors in the design and analysis of studies that assess the influence of impaired renal function on the pharmacokinetics (PK) and/or pharmacodynamics (PD) of an investigational drug and addresses how such information can inform the labeling. This guidance finalizes the draft guidance “Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing” issued on September 4, 2020.
DATES:
The announcement of the guidance is published in the Federal Register on March 18, 2024.
ADDRESSES:
You may submit either electronic or written comments on Agency guidances at any time as follows: Start Printed Page 19325
Electronic Submissions
Submit electronic comments in the following way:
• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).
Written/Paper Submissions
Submit written/paper submissions as follows:
• Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”
Instructions: All submissions received must include the Docket No. FDA–2010–D–0133 for “Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.
• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.
You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).
Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993–0002. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Martina Sahre, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., WO51/2114, Silver Spring, MD 20993–0002, 301–796–9659.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a final guidance for industry entitled “Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing.” The kidneys are involved in the elimination of many drugs, where the degree of renal excretion of unchanged drug and/or metabolites is the net result of glomerular filtration, tubular secretion, tubular reabsorption, and to a lesser degree metabolism. If a drug is eliminated primarily through renal excretion, then impaired renal function often alters the drug's PK to an extent that a change in the dosage from that used in patients with normal renal function should be considered. Literature reports indicate that impaired renal function can alter some drug metabolism and transport pathways in the liver and gut, thus there is the potential for renal impairment to also affect drugs that are predominantly cleared nonrenally. For these reasons, it is important to characterize a drug's PK in subjects with impaired renal function to provide appropriate dosage recommendations.
The safety and effectiveness of a drug are generally established for specific dosage regimens in late-phase clinical trials that enroll patients from the intended target patient population. Sometimes, individuals with impaired renal function are explicitly excluded from participation in these trials. Drug development programs should include an early characterization of the effect of impaired renal function on a drug's PK, with the goal of enabling the inclusion of this population in late-phase trials by allowing appropriate prospective dosage adjustment.
This guidance finalizes the draft guidance of the same title issued on September 4, 2020 (85 FR 55303). Revisions to the draft guidance include an expansion of the section on renal replacement therapies, especially the language related to continuous renal replacement therapy. Further revisions include an edit to the classification stages for the purpose of enrolling into a stand-alone renal impairment study.
This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on “Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Start Printed Page 19326 Budget (OMB) under the Paperwork Reduction Act (44 U.S.C. 3501–3521). The collections of information in 21 CFR 201.57 pertaining to certain prescription drug labeling have been approved under OMB control number 0910–0572. The collections of information in 21 CFR part 312 pertaining to the submission of investigational new drug applications have been approved under OMB control number 0910–0014. The collections of information in 21 CFR part 314 pertaining to the submission of new drug applications have been approved under OMB control number 0910–0001. The collections of information in 21 CFR part 601 pertaining to biologics license applications have been approved under OMB control number 0910–0338.
III. Electronic Access
Persons with access to the internet may obtain the guidance at https://www.regulations.gov, https: //www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.
Start SignatureDated: March 12, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–05683 Filed 3–15–24; 8:45 am]
BILLING CODE 4164–01–P
Document Information
- Published:
- 03/18/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice of availability.
- Document Number:
- 2024-05683
- Dates:
- The announcement of the guidance is published in the Federal Register on March 18, 2024.
- Pages:
- 19324-19326 (3 pages)
- Docket Numbers:
- Docket No. FDA-2010-D-0133
- PDF File:
- 2024-05683.pdf